271 related articles for article (PubMed ID: 22500881)
1. Pharmacokinetics of tildipirosin in porcine plasma, lung tissue, and bronchial fluid and effects of test conditions on in vitro activity against reference strains and field isolates of Actinobacillus pleuropneumoniae.
Rose M; Menge M; Bohland C; Zschiesche E; Wilhelm C; Kilp S; Metz W; Allan M; Röpke R; Nürnberger M
J Vet Pharmacol Ther; 2013 Apr; 36(2):140-53. PubMed ID: 22500881
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics of tildipirosin in bovine plasma, lung tissue, and bronchial fluid (from live, nonanesthetized cattle).
Menge M; Rose M; Bohland C; Zschiesche E; Kilp S; Metz W; Allan M; Röpke R; Nürnberger M
J Vet Pharmacol Ther; 2012 Dec; 35(6):550-9. PubMed ID: 22188102
[TBL] [Abstract][Full Text] [Related]
3. A microbiological assay to estimate the antimicrobial activity of parenteral tildipirosin against foodborne pathogens and commensals in the colon of beef cattle and pigs.
Rose M; Pridmore A; Shaw A; Wilhelm C; Menge M; Kilp S; Röpke R; Nürnberger M
J Vet Pharmacol Ther; 2016 Jun; 39(3):277-86. PubMed ID: 26538405
[TBL] [Abstract][Full Text] [Related]
4. Antibacterial activity of tilmicosin against Pasteurella multocida and Actinobacillus pleuropneumoniae isolated from pneumonic lesions in swine.
Inamoto T; Kikuchi K; Iijima H; Kawashima Y; Nakai Y; Ogimoto K
J Vet Med Sci; 1994 Oct; 56(5):917-21. PubMed ID: 7865594
[TBL] [Abstract][Full Text] [Related]
5. Optimal Regimens and Cutoff Evaluation of Tildipirosin Against
Lei Z; Liu Q; Qi Y; Yang B; Khaliq H; Xiong J; Moku GK; Ahmed S; Li K; Zhang H; Zhang W; Cao J; He Q
Front Pharmacol; 2018; 9():765. PubMed ID: 30093860
[No Abstract] [Full Text] [Related]
6. Penetration of oxytetracycline into the nasal secretions and relationship between nasal secretions and plasma oxytetracycline concentrations after oral and intramuscular administration in healthy pigs.
Bimazubute M; Cambier C; Baert K; Vanbelle S; Chiap P; Gustin P
J Vet Pharmacol Ther; 2011 Apr; 34(2):176-83. PubMed ID: 21395609
[TBL] [Abstract][Full Text] [Related]
7. PK and PK/PD of doxycycline in drinking water after therapeutic use in pigs.
Prats C; El Korchi G; Giralt M; Cristòfol C; Peña J; Zorrilla I; Saborit J; Pérez B
J Vet Pharmacol Ther; 2005 Dec; 28(6):525-30. PubMed ID: 16343284
[TBL] [Abstract][Full Text] [Related]
8. Gamithromycin in swine: Pharmacokinetics and clinical evaluation against swine respiratory disease.
Hamel D; Richard-Mazet A; Voisin F; Böhne I; Fraisse F; Rauh R; Huang R; Kellermann M; Letendre L; Dumont P; Rehbein S
Vet Med Sci; 2021 Mar; 7(2):455-464. PubMed ID: 33058489
[TBL] [Abstract][Full Text] [Related]
9. Comparison of pharmacokinetics of tilmicosin in healthy pigs and pigs experimentally infected with
Xiong J; Zhu Q; Yang S; Zhao Y; Cui L; Zhuang F; Qiu Y; Cao J
N Z Vet J; 2019 Sep; 67(5):257-263. PubMed ID: 31208293
[No Abstract] [Full Text] [Related]
10. Clinical field trials with tilmicosin phosphate in feed for the control of naturally acquired pneumonia caused by Actinobacillus pleuropneumoniae and Pasteurella multocida in swine.
Moore GM; Basson RP; Tonkinson LV
Am J Vet Res; 1996 Feb; 57(2):224-8. PubMed ID: 8633813
[TBL] [Abstract][Full Text] [Related]
11. Minimum inhibitory concentration breakpoints and disk diffusion inhibitory zone interpretive criteria for tilmicosin susceptibility testing against Pasteurella multocida and Actinobacillus pleuropneumoniae associated with porcine respiratory disease.
Shryock TR; Staples JM; DeRosa DC
J Vet Diagn Invest; 2002 Sep; 14(5):389-95. PubMed ID: 12296390
[TBL] [Abstract][Full Text] [Related]
12. Tilmicosin enteric granules and premix to pigs: Antimicrobial susceptibility testing and comparative pharmacokinetics.
Xiong J; Zhu Q; Zhao Y; Yang S; Cao J; Qiu Y
J Vet Pharmacol Ther; 2019 May; 42(3):336-345. PubMed ID: 30801755
[TBL] [Abstract][Full Text] [Related]
13. Potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida: Comparison of growth media.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():43-48. PubMed ID: 27940285
[TBL] [Abstract][Full Text] [Related]
14. Optimizing tylosin dosage for co-infection of
Lee EB; Abbas MA; Park J; Tassew DD; Park SC
Front Pharmacol; 2023; 14():1258403. PubMed ID: 37808183
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial resistance genes in Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida isolated from Australian pigs.
Dayao D; Gibson JS; Blackall PJ; Turni C
Aust Vet J; 2016 Jul; 94(7):227-31. PubMed ID: 27349882
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the potency of marbofloxacin for pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Hobson S; Lees P
Res Vet Sci; 2017 Apr; 111():93-98. PubMed ID: 28113129
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of tildipirosin in pig tonsils.
Torres F; Santamaria R; Jimenez M; Menjón R; Ibanez A; Collell M; Azlor O; Fraile L
J Vet Pharmacol Ther; 2016 Apr; 39(2):199-201. PubMed ID: 26935349
[TBL] [Abstract][Full Text] [Related]
18. Determination of minimum inhibitory and minimum bactericidal concentrations of tiamulin against field isolates of Actinobacillus pleuropneumoniae.
Pridmore A; Burch D; Lees P
Vet Microbiol; 2011 Aug; 151(3-4):409-12. PubMed ID: 21497460
[TBL] [Abstract][Full Text] [Related]
19. Mutant prevention and minimum inhibitory concentration drug values for enrofloxacin, ceftiofur, florfenicol, tilmicosin and tulathromycin tested against swine pathogens Actinobacillus pleuropneumoniae, Pasteurella multocida and Streptococcus suis.
Blondeau JM; Fitch SD
PLoS One; 2019; 14(1):e0210154. PubMed ID: 30629633
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetic/pharmacodynamic integration and modelling of florfenicol for the pig pneumonia pathogens Actinobacillus pleuropneumoniae and Pasteurella multocida.
Dorey L; Pelligand L; Cheng Z; Lees P
PLoS One; 2017; 12(5):e0177568. PubMed ID: 28552968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
